151717 Models of Partnerships for Professional Development in the Area of Drug Phenomenon in the Americas: CICAD/OAS Experience

Tuesday, November 6, 2007

Maria da Gloria Miotto Wright, PhD , Inter-American Drug Control Commission/CICAD, Organization American States/OAS, Washington, DC
Globalization process has direct or indirect impact on the drug phenomenon by increasing drug trafficking, facilitates money laundering, and increases drug use among different population groups, transforming drug phenomenon in a global problem. National policy emphasizes the importance of reducing drug use, specialy, among injecting drug users, which becomes a high risk group for HIV/AIDS. Developing countries face a lack of very well trained professionals to be able to work, teach and do research in the different aspects of the drug phenomenon in Latin America and the Caribbean Region. CICAD, for the last twenty years, has assumed the responsibility and challenge to develop innovative models of partnerships with universities, research centers and other organizations through out the Americas to assist Latin America and the Caribbean countries to dimish the impact of this situation. The purpose of this presentation is to share the results and experiences of CICAD/OAS in developing different models of partnerships with universities, research centers, international organizations and national drug control commissions to train health and other professionals to work, teach and do research in the area of drug phenomenon.

Learning Objectives:
Learn about CICAD/OAS drug control policy for the Americas; Assess information about different models of partnership for professional development in the area of drug phenomenon; Identify the results and products of different models of partnership CICAD/OAS has implemented in the Americas.

Keywords: Drugs, Partnerships

Presenting author's disclosure statement:

Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.